The protracted and often debilitating sequelae of a SARS-CoV-2 infection, colloquially known as long COVID or post-acute sequelae of COVID-19 (PASC), continue to pose a profound global health challenge, affecting millions worldwide. Characterized by a constellation of symptoms persisting for months after the initial illness, long COVID has remained largely enigmatic, with its underlying biological mechanisms poorly understood, hindering the development of effective, evidence-based treatments. However, groundbreaking research emerging from the Centre for Addiction and Mental Health (CAMH) in Canada is shedding critical new light on this complex condition, presenting what scientists describe as the most compelling evidence to date linking long COVID to tangible damage within the brain’s dopamine-releasing neuronal networks. These pivotal findings, recently published in the esteemed journal eBioMedicine, not only offer a robust biological explanation for some of the most pervasive symptoms experienced by long COVID sufferers—such as profound fatigue, diminished motivation, slowed motor functions, and significant cognitive impairments—but also crucially chart a promising new course for targeted therapeutic interventions.
Long COVID’s reach is extensive and deeply impactful, with estimates suggesting it afflicts approximately five percent of the global population. In Canada alone, this translates to roughly two million individuals grappling with a diverse array of symptoms that endure for a minimum of three months post-infection. The spectrum of these symptoms is remarkably broad, encompassing respiratory difficulties, cardiovascular irregularities, musculoskeletal pain, and gastrointestinal issues. Yet, among the most distressing and debilitating manifestations are those impacting the central nervous system, frequently termed "brain fog," alongside persistent fatigue, memory deficits, and mood disturbances like low mood or anhedonia. The pervasive nature of these neurological complaints significantly diminishes quality of life, often rendering individuals unable to return to their previous levels of social, professional, or personal functioning. Despite the immense societal burden and individual suffering, a critical void persists in the medical landscape: the absence of established, evidence-based treatments, a predicament largely attributable to the scientific community’s incomplete understanding of the specific neurobiological changes underpinning the condition.
To bridge this knowledge gap, the CAMH-led research team embarked on an ambitious study employing positron emission tomography (PET), an advanced medical imaging technique that provides a unique window into the living brain’s biochemical and metabolic activities. Unlike structural imaging methods that capture anatomical details, PET scans can quantify the distribution and density of specific molecules, receptors, or transporters, thereby offering insights into neuronal health and function. In this particular investigation, researchers meticulously measured a well-established neurochemical marker indicative of the health and structural integrity of dopamine-producing neurons. This marker, often related to dopamine transporter availability, reflects the density of dopamine nerve terminals, which are the specialized endings of neurons responsible for releasing dopamine into the synaptic cleft. A reduction in this marker typically signifies a loss or impairment of these vital dopaminergic nerve terminals. The research involved a cohort of individuals diagnosed with long COVID, whose brain scans were then rigorously compared against those from a group of healthy control participants, ensuring a clear contrast to identify any pathological deviations.
The results of the PET imaging analysis revealed striking and statistically significant differences between the two groups. Individuals experiencing long COVID exhibited substantially lower levels of the dopamine neuron integrity marker across all major subdivisions of the striatum. The striatum is a critically important subcortical brain region, forming a cornerstone of the basal ganglia system, which plays an integral role in a multitude of higher-order brain functions. Functionally, the striatum is deeply involved in regulating voluntary movement, orchestrating motivation, facilitating reward processing, shaping habit formation, and contributing significantly to various aspects of cognition, including working memory and decision-making. The observed reduction in this marker points directly to a decreased density of dopamine nerve terminals within these pivotal striatal regions, implying a tangible compromise to the very neurons responsible for synthesizing and releasing dopamine.
Further analysis delved into the specific symptomatic correlations associated with these regional reductions in dopamine markers, yielding highly granular insights. The study identified distinct patterns of marker loss linked to particular neurological symptoms. For instance, lower levels of the dopamine marker within the ventral striatum were found to be strongly associated with a greater reported loss of motivation and anhedonia, a diminished capacity to experience pleasure. The ventral striatum, often referred to as the brain’s "reward circuit," is central to the processing of pleasure, reward, and motivation, and its dopaminergic activity is crucial for goal-directed behavior. Separately, reductions observed in the dorsal putamen, another key striatal subregion predominantly involved in motor control and habit learning, correlated directly with slower movement and motor difficulties experienced by patients. Concurrently, diminished marker levels in the caudate putamen, which plays a significant role in cognitive functions, including memory and learning, were robustly connected with documented memory difficulties. These specific correlations powerfully underscore the direct link between compromised dopaminergic pathways and the specific neurological symptoms of long COVID.
Dr. Jeffrey Meyer, a Senior Scientist at the Brain Health Imaging Centre, Canada Research Chair, and the senior author of this seminal study, articulated the significance of these findings. "Our research provides compelling evidence that long COVID involves a measurable loss of dopamine-releasing neurons," Dr. Meyer stated. "This type of neuronal injury is well-established in neurological conditions for producing symptoms such as a profound lack of motivation and motor slowing, and it can also contribute to memory difficulties. Our results strongly suggest that a similar pathophysiological process is at play in long COVID." This statement highlights the profound implications of the study, drawing parallels to other known neurological disorders where dopaminergic dysfunction is a central feature.
Crucially, these new discoveries do not exist in isolation but rather build upon prior research conducted by the very same team. Earlier investigations had already revealed that individuals with long COVID exhibit unusually elevated levels of inflammation within the brain. This neuroinflammation, a sustained immune response within the central nervous system, appeared to be particularly pronounced in precisely those brain regions that are densely populated with dopamine-releasing neurons. Dr. Meyer elaborated on this crucial connection, explaining, "We have long understood that persistent inflammation can inflict damage upon dopamine neurons. While our previous studies clearly demonstrated high levels of inflammation in these critical brain regions, this latest study provides the direct, irrefutable evidence that the dopamine neuron marker is indeed reduced in these identical regions—and, critically, that this loss precisely correlates with the patients’ reported symptoms." When considered collectively, these two complementary studies paint a coherent picture, strongly suggesting a causal link where sustained brain inflammation, a hallmark of long COVID, precipitates or contributes to the observed damage within the dopaminergic system.
The ramifications of these findings extend far beyond merely elucidating the disease mechanism; they stand to fundamentally reshape the scientific community’s approach to understanding the biology of long COVID and, more importantly, to developing effective treatments. Much of the earlier research and therapeutic exploration for long COVID had predominantly focused on broader aspects of brain inflammation and generalized alterations in immune system activity. While these avenues remain important, the current study redirects attention to a specific neurotransmitter system—the dopamine system—which has received comparatively little direct focus in clinical trials for long COVID. This shift represents a significant paradigm change, offering a more precise target for therapeutic intervention.
"These results unequivocally indicate that long COVID is, at least in part, a disorder profoundly affecting the brain’s dopamine system," Dr. Meyer added, emphasizing the transformative potential of this insight. "This robust finding strongly suggests that repurposing existing medications designed to augment the function of dopamine-releasing neurons could represent a highly promising therapeutic strategy." Such medications could include dopamine precursors, substances that the brain converts into dopamine (e.g., L-DOPA, though the study does not specify particular drugs), or inhibitors of dopamine metabolism, which prolong the action of dopamine by slowing its breakdown in the brain (e.g., MAO-B inhibitors, COMT inhibitors). By directly addressing the identified dopamine deficit, these approaches could potentially alleviate the debilitating fatigue, improve motivation, and enhance cognitive function in long COVID patients. The prospect of repurposing existing drugs is particularly appealing, as these medications have already undergone extensive safety testing, potentially accelerating their deployment in long COVID clinical trials.
For the millions of individuals currently living with the often invisible and poorly understood symptoms of long COVID, these scientific findings offer more than just academic insight; they provide profound validation and a beacon of hope. Many long COVID sufferers have reported a frustrating lack of understanding from medical professionals, and the absence of clear biological markers has often led to their symptoms being dismissed or attributed to psychological factors. Susan Deuville, a lived experience research advisor to Dr. Meyer and a long COVID patient herself, powerfully articulated this sentiment. "For five years, I have been desperately seeking answers on what precisely happened to me after I contracted COVID in 2021," she shared. "It represented a crushing loss of the life I had known and the very person I was before. Dr. Meyer’s groundbreaking research brings immense hope. It also profoundly validates what long COVID sufferers have intuitively known all along—that long COVID is unequivocally real, and its effects are truly devastating." This personal testimony underscores the critical importance of biological explanations in recognizing the legitimacy of a chronic illness and providing comfort and direction to those affected.
Building directly upon these compelling results, the research team is not resting on its laurels. They have already initiated plans for a pivotal clinical trial, slated to commence in the coming months, specifically designed to target dopamine function in individuals afflicted with long COVID. The overarching goal of this forthcoming trial will be to rigorously determine whether judiciously modifying dopamine activity can lead to measurable improvements in the core symptoms of memory, motivation, and fatigue. This critical next step will involve a collaborative effort with University Health Network (UHN), forming part of an innovative partnership between the two leading hospitals, specifically aimed at bridging the historical divide between mental and physical health care. This integrated approach acknowledges the complex interplay between neurological and psychological symptoms in long COVID.
The journey to fully unravel the mysteries of long COVID is undoubtedly long and arduous. However, this pioneering research from CAMH represents a monumental leap forward, providing a concrete, biological foundation for some of the most pervasive and debilitating symptoms of the condition. By identifying a specific mechanism of neuronal damage within the brain’s crucial dopamine system, the study not only advances our fundamental understanding but also illuminates a clear, actionable pathway for the development of targeted, evidence-based therapies. Supported by crucial funding from the Canadian Institutes of Health Research (CIHR), this work not only holds the promise of transforming treatment paradigms but also offers invaluable validation and renewed hope to millions globally who are navigating the complex and often isolating reality of long COVID.
About the Author
